Navigation Links
XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration
Date:6/4/2009

MENLO PARK, Calif., June 4 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that the Company received conditional approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) authorizing it to begin its pivotal clinical program, composed of two pivotal trials called CUSTOM IV and CUSTOM IV Angio to support the approval in the United States of its Custom NX(R) Drug Eluting Stent (DES) System. The conditional approval requires the Company to address some technical issues about which the FDA has questions prior to granting full approval.

"This conditional approval further demonstrates the progress made in the development of a truly revolutionary drug eluting stent system," said Greg Casciaro, President and Chief Executive Officer of XTENT, Inc. "I want to recognize each and every XTENT employee, and especially Dr. Philippe Marco, our Vice President of Quality Assurance, Clinical and Regulatory Affairs, for their dedication and efforts in introducing a new drug and coating formulation along with a new delivery platform through this regulatory process. We also must credit the active participation and support of our BA-9/PLA licensor, Biosensors."

"This is a significant milestone for a technology that was designed to treat today's complex patient population that presents with multi-vessel coronary artery disease and/or long lesions," said Martin B. Leon, M.D., Associate Director of the Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center. "It will be a missed opportunity if this technology does not carry forward in development quickly as it not only potentially fills the unmet clinical needs we have today, but it may also address the increasing cost pressures faced by the global healthcare system
'/>"/>

SOURCE XTENT, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. XTENT, Inc. Announces Approval of Plan of Liquidation and Dissolution by Board of Directors and Filing of Proxy Materials With the SEC
2. Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
3. Innovia Receives FDA Clearance For The InnoPort(TM)
4. Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM)
5. Respected Surgeon Receives Emmy Nomination
6. Edward Diehl Receives Outstanding Achievement Award From the American College of Addiction Treatment Administrators (ACATA)
7. LA BioMed researcher receives clinical teaching award
8. SAFC Pharmas St. Louis HPAPI Conjugates Facility Receives SafeBridge Certification
9. ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
10. Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis (Pink Eye)
11. Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... WEST PALM BEACH, Fla. , Feb. 9 /PRNewswire-USNewswire/ ... a grant awarded to the School District of Palm ... eat right and get fit. The Robert Wood Johnson Foundation ... opportunities for physical activity and access to affordable healthy foods ... and Palm Springs communities. Based on a rigorous ...
(Date:2/9/2010)... iPhone application created by UH researchers is providing ... world. Those annual rankings of America,s fattest and ... host of indirect indicators may soon have a ... the University of Houston provides objective data. , ... from Apple,s "App Store," allows users to keep ...
(Date:2/9/2010)... increased in infants born prematurely in the US, according ... System (LUHS). These findings were reported at the 30th ... Chicago. They also were published in the latest issue ... . , Researchers reported that CP is associated with ... This inflammation is more common in premature births from ...
(Date:2/9/2010)... type II audit is a significant achievement and differentiates ... , ... (PRWEB) February 9, 2010 ... announced that it has successfully completed a Statement on Auditing ... by McGladrey & Pullen, LLP and covered Hallmark Insights operational ...
(Date:2/9/2010)... men with fewer complications, study finds , , TUESDAY, Feb. ... are more likely than men to fail catheter ablation ... procedures five times as often as women and usually ... February issue of HeartRhythm Journal , are based ... and 2008. They underwent pulmonary vein antrum isolation, a ...
Breaking Medicine News(10 mins):Health News:Planting Seeds to Fight Childhood Obesity 2Health News:Phone app providing real-time statistics on physical activity around the world 2Health News:Phone app providing real-time statistics on physical activity around the world 3Health News:Incidence of cerebal palsy on rise in United States 2Health News:Hallmark Insights Completes SAS 70 Type II Audit 2
... Three studies to be presented at Teenage Cancer Trust,s Fifth ... (Monday) have thrown light on the extent of delays that ... with cancer, and on some of the reasons why this ... Cancer at the University of Manchester, UK, will tell the ...
... to 75 with type 2 disease have same odds for condition, ... adults with type 2 diabetes run much less risk than previously ... to the heart, according to a new study. , ... diabetes run the same risk of having a cardiac condition whether ...
... presenting with one checked for other , , SATURDAY, ... between type 2 diabetes and obstructive sleep apnea (OSA) ... the International Diabetes Federation warns. , Up to 40 ... also have diabetes, recent studies suggest. Likewise, more than ...
... Echocardiography System to Acquire, Instantaneous, Non-Stitched Full-Volume Images of the ... ... Heartbeat, TORONTO, June 7 Siemens Healthcare, (http://www.usa.siemens.com/healthcare ) ... the world to acquire,non-stitched, real-time full-volume 3D images of the heart ...
... Event Becomes "Susan G. Komen GLOBAL Race for ... National Mall was,passionately pink this morning, as nearly ... for the 19th annual Susan,G. Komen National Race ... to fund breast cancer research and community health ...
... Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the ... of China ("PRC"),today announced the successful completion of ... May 29, 2008., Tianma pills, one of ... the treatment of headaches. The primary,active ingredient in ...
Other Medicine News:Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 2Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 3Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 4Health News:Older Diabetics' Risk of Cardiac Ischemia Lower Than Thought 2Health News:Doctors Urged to Look for Link Between Type 2 Diabetes, Sleep Apnea 2Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 2Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 3Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 2Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 3Health News:Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent 2Health News:Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent 3
(Date:2/9/2010)... -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ... tender offer for all outstanding shares of common stock ... offer and withdrawal rights expired at 12:00 midnight, ... 2010 .  The depositary for the tender offer has ... 18,611,072 shares of Chattem common stock (including approximately 2,853,283 ...
(Date:2/8/2010)... Feb. 8 Rapid developments in ... increase in the use and cost of "specialty" ... and psoriasis. This has led to some inappropriate ... and medication coverage being spread over both pharmacy ... solution with Medication Cost Integration (MCI), which covers ...
(Date:2/8/2010)... 8 Transgenomic, Inc. (OTC Bulletin ... a preliminary study with a leading pharmaceutical company ... technology to detect colorectal tumor-associated KRAS mutations that ... detected in plasma samples in which the mutation ... DNA analysis methodologies such as Sanger sequencing. ,, ...
Breaking Medicine Technology:Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 2Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 3Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 4Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 5RegenceRx Leads the Industry With Introduction of Medication Cost Integration 2RegenceRx Leads the Industry With Introduction of Medication Cost Integration 3Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 2Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 3Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 4 26quot 3BJesse 26apos 3Bs Story 26quot 3B to Open The 10th Annual Malibu Film Festival 53500 1 26quot 3BJesse 26apos 3Bs Story 26quot 3B to Open The 10th Annual Malibu Film Festival 53500 2 26quot 3BJesse 26apos 3Bs Story 26quot 3B to Open The 10th Annual Malibu Film Festival 53500 3U S Fund for UNICEF and Major League Soccer Kick Off Partnership to Save Childrens Lives 53499 1U S Fund for UNICEF and Major League Soccer Kick Off Partnership to Save Childrens Lives 53499 2U S Fund for UNICEF and Major League Soccer Kick Off Partnership to Save Childrens Lives 53499 3Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 1Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 2Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 3
... Study Also Showed Arzoxifene Significantly Suppressed Bone Turnover ... Greece, March 23 Eli Lilly and Company ... showing arzoxifene, an investigational selective estrogen receptor modulator ... mineral density (BMD) in the lumbar spine, total ...
... YORK, March 20 InnoCentive, Inc., ... Publishing Group (NPG) , a leading scientific and ... greater scientific collaboration and open innovation.Under the agreement, ... the involvement of scientists worldwide in solving global ...
Other Medicine Technology:Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 2InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 3InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 4
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
... Off-white free flowing powder. pH: pH(4.7%, ... Casein Peptone: 24% Yeast Extract: 47% Potassium Phosphate ... To Use: Dissolve 47 gm powder per liter ... of plasmid DNA and recombinant proteins than LB ...
...
Medicine Products: